Navigation Links
MiMedx Announces 2012 Results
Date:3/7/2013

business, and the expected quarterly revenue growth. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the direct sales force strategy will not continue to produce quarter-over-quarter sales growth, that the clinical study results will not be as positive as anticipated or will not enable the Company to capture additional market presence, that a new patent will not issue in the near term  or that the claims, if any, allowed will be substantially reduced, that competitors can "design around" the Company's patents; that the Company may not be successful in entering into new placenta recovery contracts, that the Company's existing and future placental recovery contracts will not be sufficient to meet the Company's demand for tissue,  that the reimbursement coverage in the Medicare and commercial sectors does not materialize or expands at a rate slower than anticipated, that VA and government business will not continue to increase, that quarterly revenue growth will be below expectations, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2011. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

 MIMEDX GROUP, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS Years Ended December 31,REVENUES:20122011Net sales$
27,053,773$
7,760,446OPERATING COSTS AND EXPENSES:Cost of products sold

5,188,3783,357,909Research and development expenses

'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. MiMedx Group to Present at the 6th Annual OneMedForum
2. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. CCS Medical Announces Agreement with LifeScan
4. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
5. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. DMH International Announces The Launch of TouchPACS
9. Psyche Systems Announces Availability of Toxicology LIS
10. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
11. DDS Lab Announces Strategic Alliance with United Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015 Lucerne Biosciences, LLC announced ... of U.S. Patent Application No. 14/464,249 entitled "Method ... features claimed methods of "informing a user" that ... Binge Eating Disorder (,BED,)," including by reference to ... an advertisement," as well as by presentation of ...
(Date:3/5/2015)... DIEGO , March 5, 2015  Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its fourth quarter and full year ... March 16, 2015, before the market opens for ... will host a conference call to discuss the ...
(Date:3/5/2015)... Germany , March 5, 2015 ... and CureVac today announced that the foundation has ... million) in CureVac, a leading clinical-stage biopharmaceutical company ... the agreement, the foundation will also provide separate ... based on CureVac,s proprietary messenger RNA (mRNA) platform. ...
Breaking Medicine Technology:Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate 2Pfenex To Report Fourth Quarter and Full Year 2014 Results and Provide Business Update 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4
... TALLAHASSEE, Fla., March 11, 2011 The Florida Society ... latest facts on Oxycodone and Hydrocodone use in the ... available to the public or media.  Oxycodone dispensed in ... 2009 ARCOS report, US Census and FDA.Translation from grams ...
... 2011 Mylan Inc. (Nasdaq: MYL ) ... the company,s credit ratings, including the "Corporate Family Rating," ... Moody,s rating outlook is stable.   According ... trends accomplished through new product launches, a strong global ...
Cached Medicine Technology:Florida Pain Clinic Society: 3.7 Billion Oxycodone Tablets Dispensed in U.S. 2Moody's Upgrades Mylan 2
(Date:3/6/2015)... (PRWEB) March 06, 2015 “ Pokemini ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... game. , Over the last couple of years, mobile ... to the game. For example, Candy Crush allows users to ...
(Date:3/6/2015)... San Jose, California (PRWEB) March 06, 2015 ... cancer is one of the most common forms of ... women worldwide. Breast cancer can be screened through various ... among others. Mammography however remains the gold standard technique ... factors such as cost, time taken for the procedure, ...
(Date:3/6/2015)... New York, New York (PRWEB) March 06, 2015 ... tap dancing’s dazzling days on the grand stage, to the ... Legacy Dancers sparkle throughout with precision toe-tapping numbers and their ... and Karyn Tomczak deliver the rich history of tap dancing ... dance forms to come out of the United States. ...
(Date:3/6/2015)... As the Association of American ... 90,000 doctors by 2025 is updated this week and ... is proactively preparing by analyzing demographics and pursuing viable ... , Several factors including the increasing number of retiring ... the Affordable Care Act and an uneven distribution of ...
(Date:3/6/2015)... 06, 2015 Jvion, the Atlanta-based ... of a Clostridium Difficile (C Diff) predictive use ... Diff use case is the latest in a ... acquired infections, chronic conditions, and individual illnesses. Using ... Diff solution flags at risk individuals to help ...
Breaking Medicine News(10 mins):Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 2Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 3Health News:Susquehanna Health Plans Progressively to Prevent Projected Physician Shortfall 4Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... small capsule-shaped bacteria. The immune cells which help protect us ... in space travellers and it could be something to do ... (JSC) have been studying how immune cells behave in microgravity ... space on astronauts.// ,It has been found that astronauts ...
... approved the first pocket-sized EKG machine, so small ... ambulances, the emergency room - even a possible ... hand-held computer-based medical device, part of a growing ... equipment. ,Electrocardiograms, also called EKGs or ECGs, ...
... will probably be prescribed cholesterol-lowering drugs as a result ... cautions that the effects of those medications in that ... Cholesterol Education Program guidelines, about 15 million Americans between ... considered candidates taking statin group of drugs for ...
... claim that just by looking at a person's face could ... is that smokers age faster than non smokers.A study by ... genes responsible for a skin enzyme that breaks down collagen ... of the skin and maintains the elasticity of the skin. ...
... have devised that each cigarette cuts on average 12 minutes ... the difference in life expectancy between smokers and non-smokers and ... male smoker might consume in a lifetime. ,The researchers, ... expectancy from a major study of the impact of// smoking ...
... after a couple of drinks is a common problem for ... was a mystery until now.It may support the potentialities of ... College of Medicine and the Mayo Clinic in Minnesota say ... accused.// They found, in a study of healthy young adults, ...
Cached Medicine News:Health News:Immune cells halt round in space 2
... CSV- lOOOHGT instrument provides standardized glare testing. It ... test faces for the evaluation of glare disability. ... precisely calibrated to simulate two on-coming halogen car ... The glare level can be adjusted to simulate ...
Designed to determine the precise length of limbal incisions and proper alignment of closing sutures. Curved marking blade with 2 mm lines spaced 1 mm apart-measures up to 10 mm. Round knurled handle...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: